Physician profile
Stephen B Pollack
NPI 1760468409
$6,443.87
in general payments reported to CMS, 2019-2025
24 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $621 · 2021: $591 · 2022: $884 · 2023: $756 · 2024: $1,380 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,767.92 | 2019-2025 | Rocklatan, Argos, Hydrus Microstent |
| Abbvie INC. | $945.56 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $764.89 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $607.51 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $395.50 | 2019-2024 | Cequa, Xelpros |
| Allergan, INC. | $380.25 | 2019-2022 | |
| Sight Sciences, INC. | $341.46 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $257.18 | 2019-2021 | |
| Amgen INC. | $129.41 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $128.93 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $124.99 | 2024 | Syfovre |
| Omeros Corporation | $119.86 | 2019 | |
| Oyster Point Pharma, INC. | $102.87 | 2024-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.58 | 2019-2020 | |
| Shire North American Group INC | $46.33 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $36.54 | 2025 | Idosetr |
| Harrow Eye, LLC | $33.18 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $28.86 | 2020-2022 | |
| Rxsight INC | $28.34 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Regeneron Healthcare Solutions, INC. | $26.39 | 2023 | Eylea Hd |
| Rayner Intraocular Lenses Limited | $26.32 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Thea Pharma INC. | $23.49 | 2025 | Iyuzeh |
| Dompe US, INC. | $23.37 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $15.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.